You'll never guess what happened next...

"The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug, and more copycats were close behind. The onset of competition seemed likely to push down the medication’s $50,000-a-year list price."

#TNF #RheumatoidArthritis #lupus #PublicHealth #Humira #MonoclonalAntibody

https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html